We provide nutrition services, which includes lab testing. We will even look at labs you previously had done. These services will help give you the definite answers to what supplements your body needs.
Call our office today to set up your nutritional counseling session!
Vascular Disease and SPMs (OmegaGenics® SPM Active)
Author: J. Troup
Coronary Artery Disease (CAD) is the most common form of heart disease and is a leading cause of death in the United States among both men and women. Indeed, in 2012, 17.5 million people died from heart disease worldwide, and 7.4 million of those died from CAD. CAD develops when plaque forms in the coronary arteries, limiting and blocking blood flow. Another cause of CAD, in addition to arterial plaques, is arterial inflammation. A new study by Tarec K. Elajami and colleagues, published in April 2016 has found resolution of inflammation in the body may also lead to clot remodeling and reduce the incidence of CAD and coronary events in at risk patients.
The resolution phase of inflammation is facilitated in the body by specialized proresolving mediators (SPMs) which include lipoxins, resolvins, protectins, and maresins which enhance microbial clearance as well as a variety of other functions including tissue remodeling, host defense, and others. Studies with patients with chronic inflammatory diseases such as cystic fibrosis, metabolic syndrome,
asthma, and periodontal disease have lower levels of SPMs than do control participants.With regards to vascular disease, it has also been found that patients with peripheral arterial disease have significantly lower levels of 17-HDHA than healthy subjects. These examples show that levels of SPMs may be lower in patients with chronic inflammatory diseases. Accordingly, Elajami et al. hypothesized patients with CAD having lower levels of SPMs, subsequently prevent them from resolving arterial inflammation and ultimately lead to the progression of CAD.
In the study conducted by Elajami et al., six men with stable CAD and lower than normal SPM levels were randomly assigned to take 3.36 g of an FDA-approved pharmacological therapy designed to increase circulating availability of SPMs, ( precursors of SPMs / OmegaGenics® SPM Active), daily for one year. EPA and DHA have been shown to reduce the risk of cardiovascular events. After one year of this treatment, patients who took the treatment, had twice the levels of proresolving and anti-inflammatory mediators as did those who did not take the nutritional treatment, and lower levels of prostaglandins compared to those who did not take use the treatment.
After one year of supplementation, CAD patients had more favorable SPM profiles, including improvements in lipid mediation and specific SPM biosynthesis. While the resolution properties of SPMs are known. This study indicates that a year of high-dose supplementation that increases availability of SPMs is highly effective. The results of this study indicate that supplementing the diet to increase SPMs may reduce the progression of atherosclerosis and CAD.
Recently standardized SPM were introduced into the market. These SPM supplements are standardized to level of SPMs and activity. SPMs have a strong potential as new therapeutic strategies for inflammatory diseases, including CAD. Learn more about SPMs at MHICN.com.
Elajami, TK; RA Colas; J Dalli; N Chiang; CN Serhan; FK Welty. Specialized Proresolving Lipid Mediators in Patients with Coronary Artery Disease and their Potential for Clot Remodeling. FASEB Journal. 2016 Apr 27.http://www.fasebj.org/
Fredman, G; SF Oh; S Ayilavarapu; H Hasturk; CN Serhan; TE Van Dyke. Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS One. 2011; 6(9). http://www.ncbi.nlm.nih.
Ho, KJ; M Spite; CD Owens; H Lancero; AH Kroemer; R Pande; MA Creager; CN Serhan; MS Conte. Aspirin-triggered lipoxin and resolving E1 modulate vascular smooth muscle phenotype and correlate with peripheral atherosclerosis. Am J Pathol. 2010; 177(4):2116-23. http://
Karp, CL; LM Flich; KW Park; S Softic; TM Greer; R Keledijan; R Yang; J Uddin; WB Guggino; SF Atabani; Y Belkaid; Y Xu; JA Whitsett; FJ Accurso; M Willis-Karp; NA Petasis. Defective Lipoxin-Mediated Anti-Inflammatory Activity in the Cystic Fibrosis Airway. Nat Immunol. 2004;5(4):388-92.http://www.
Levy, BD; C Bonnans; ES Silverman; LJ Palmer; G Marigowda; E Israel; Severe Asthma Research Program, National Heart, Lung, and Blood Institute. Diminished Lipoxin Biosynthesis in Severe Asthma. Am J Respir Crit Care Med. 2005;172(7):824-30. http://